|
1
|
Buys SS, Partridge E, Black A, et al: PLCO
Project Team: Effect of screening on ovarian cancer mortality: The
Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening
Randomized Controlled Trial. JAMA. 305:2295–2303. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Matsuda A and Katanoda K: Five-year
relative survival rate of ovarian cancer in the USA, Europe and
Japan. Jpn J Clin Oncol. 44:1962014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Malek JA, Mery E, Mahmoud YA, et al: Copy
number variation analysis of matched ovarian primary tumors and
peritoneal metastasis. PLoS ONE. 6:e285612011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Brandhagen BN, Tieszen CR, Ulmer TM, Tracy
MS, Goyeneche AA and Telleria CM: Cytostasis and morphological
changes induced by mifepristone in human metastatic cancer cells
involve cytoskeletal filamentous actin reorganization and
impairment of cell adhesion dynamics. BMC Cancer. 13:352013.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
von Nandelstadh P, Gucciardo E, Lohi J, Li
R, Sugiyama N, Carpen O and Lehti K: Actin-associated protein
palladin promotes tumor cell invasion by linking extracellular
matrix degradation to cell cytoskeleton. Mol Biol Cell.
25:2556–2570. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yamaguchi H and Condeelis J: Regulation of
the actin cytoskeleton in cancer cell migration and invasion.
Biochim Biophys Acta. 1773:642–652. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Rane CK and Minden A: P21 activated
kinases: Structure, regulation, and functions. Small GTPases.
5:52014. View Article : Google Scholar
|
|
8
|
Zhu J, Attias O, Aoudjit L, Jiang R,
Kawachi H and Takano T: p21-activated kinases regulate actin
remodeling in glomerular podocytes. Am J Physiol Renal Physiol.
298:F951–F961. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Abo A, Qu J, Cammarano MS, Dan C, Fritsch
A, Baud V, Belisle B and Minden A: PAK4, a novel effector for
Cdc42Hs, is implicated in the reorganization of the actin
cytoskeleton and in the formation of filopodia. EMBO J.
17:6527–6540. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bompard G, Rabeharivelo G, Cau J, Abrieu
A, Delsert C and Morin N: P21-activated kinase 4 (PAK4) is required
for metaphase spindle positioning and anchoring. Oncogene.
32:910–919. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Paliouras GN, Naujokas MA and Park M:
PAK4, a novel Gab1 binding partner, modulates cell migration and
invasion by the Met receptor. Mol Cell Biol. 29:3018–3032. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Dart AE and Wells CM: P21-activated kinase
4 - not just one of the PAK. Eur J Cell Biol. 92:129–138. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wells CM, Whale AD, Parsons M, Masters JR
and Jones GE: PAK4: A pluripotent kinase that regulates prostate
cancer cell adhesion. J Cell Sci. 123:1663–1673. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Minden A: The pak4 protein kinase in
breast cancer. ISRN Oncol. 2012:6942012012.PubMed/NCBI
|
|
15
|
Guo Q, Su N, Zhang J, Li X, Miao Z, Wang
G, Cheng M, Xu H, Cao L and Li F: PAK4 kinase-mediated SCG10
phosphorylation involved in gastric cancer metastasis. Oncogene.
33:3277–3287. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Siu MK, Chan HY, Kong DS, et al:
p21-activated kinase 4 regulates ovarian cancer cell proliferation,
migration, and invasion and contributes to poor prognosis in
patients. Proc Natl Acad Sci USA. 107:18622–18627. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tokarz P and Blasiak J: The role of
microRNA in metastatic colorectal cancer and its significance in
cancer prognosis and treatment. Acta Biochim Pol. 59:467–474.
2012.PubMed/NCBI
|
|
18
|
Zaman MS, Maher DM, Khan S, Jaggi M and
Chauhan SC: Current status and implications of microRNAs in ovarian
cancer diagnosis and therapy. J Ovarian Res. 5:442012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Luo J, Zhou J, Cheng Q, Zhou C and Ding Z:
Role of microRNA-133a in epithelial ovarian cancer pathogenesis and
progression. Oncol Lett. 7:1043–1048. 2014.PubMed/NCBI
|
|
20
|
Frampton AE, Krell J, Jacob J, Stebbing J,
Castellano L and Jiao LR: Loss of miR-126 is crucial to pancreatic
cancer progression. Expert Rev Anticancer Ther. 12:881–884. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Feng R, Chen X, Yu Y, Su L, Yu B, Li J,
Cai Q, Yan M, Liu B and Zhu Z: miR-126 functions as a tumour
suppressor in human gastric cancer. Cancer Lett. 298:50–63. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Cristóbal I, Aguilera O, García-Foncillas
J, Zazo S, Madoz-Gúrpide J and Rojo F: Clinical significance of
miR-126 in colorectal cancer. Genes Chromosomes Cancer. 53:8812014.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sun Y, Bai Y, Zhang F, Wang Y, Guo Y and
Guo L: miR-126 inhibits non-small cell lung cancer cells
proliferation by targeting EGFL7. Biochem Biophys Res Commun.
391:1483–1489. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Menges CW, Sementino E, Talarchek J, Xu J,
Chernoff J, Peterson JR and Testa JR: Group I p21-activated kinases
(PAKs) promote tumor cell proliferation and survival through the
AKT1 and Raf-MAPK pathways. Mol Cancer Res. 10:1178–1188. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kumar R, Gururaj AE and Barnes CJ:
p21-activated kinases in cancer. Nat Rev Cancer. 6:459–471. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Siu MK, Chan HY, Kong DS, et al:
p21-activated kinase 4 regulates ovarian cancer cell proliferation,
migration, and invasion and contributes to poor prognosis in
patients. Proc Natl Acad Sci USA. 107:18622–18627. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Fu X, Feng J, Zeng D, Ding Y, Yu C and
Yang B: PAK4 confers cisplatin resistance in gastric cancer cells
via PI3K/Akt- and MEK/Erk-dependent pathways. Biosci Rep. 34:59–67.
2014. View Article : Google Scholar
|
|
28
|
Zhang J, Wang J, Guo Q, Wang Y, Zhou Y,
Peng H, Cheng M, Zhao D and Li F: LCH-7749944, a novel and potent
p21-activated kinase 4 inhibitor, suppresses proliferation and
invasion in human gastric cancer cells. Cancer Lett. 317:24–32.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Huang F, Zhu X, Hu XQ, Fang ZF, Tang L, Lu
XL and Zhou SH: Mesenchymal stem cells modified with miR-126
release angiogenic factors and activate Notch ligand Delta-like-4,
enhancing ischemic angiogenesis and cell survival. Int J Mol Med.
31:484–492. 2013.PubMed/NCBI
|
|
30
|
Li L, Huang K, You Y, Fu X, Hu L, Song L
and Meng Y: Hypoxia-induced miR-210 in epithelial ovarian cancer
enhances cancer cell viability via promoting proliferation and
inhibiting apoptosis. Int J Oncol. 44:2111–2120. 2014.PubMed/NCBI
|
|
31
|
Zhang Y, Wang X, Xu B, Wang B, Wang Z,
Liang Y, Zhou J, Hu J and Jiang B: Epigenetic silencing of miR-126
contributes to tumor invasion and angiogenesis in colorectal
cancer. Oncol Rep. 30:1976–1984. 2013.PubMed/NCBI
|
